Gastroesophageal Junction Cancer Clinical Trials

96 clinical trials for Gastroesophageal Junction Cancer across international registries, including 37 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE3
• Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer — RECRUITING · PHASE2
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 — RECRUITING · PHASE2
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors — RECRUITING · PHASE1
• Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer — RECRUITING · NA
• A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• Registry for Esophageal and Gastroesophageal Junction Cancer — RECRUITING
• IKS014 in Advanced Solid Tumors That Express HER2 — RECRUITING · PHASE1
• CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer — RECRUITING · PHASE1
• Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer — RECRUITING · NA
• A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer — RECRUITING · PHASE3
• A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer — RECRUITING · PHASE2
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas — RECRUITING · PHASE1
• Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05) — RECRUITING · PHASE3
• A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977) — RECRUITING · PHASE2
• A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS — RECRUITING · PHASE1
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer — RECRUITING · PHASE2
• XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma — RECRUITING · PHASE2
• Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma — RECRUITING · PHASE2
• A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA — RECRUITING · PHASE3
• A PHASE 1B/3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY AND NIVOLUMAB VERSUS CHEMOTHERAPY AND NIVOLUMAB ALONE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE 102) — RECRUITING · PHASE1
• A RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE 101) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) PLUS LENVATINIB (E7080/MK-7902) PLUS CHEMOTHERAPY COMPARED WITH STANDARD OF CARE THERAPY AS FIRST-LINE INTERVENTION IN PARTICIPANTS WITH ADVANCED/METASTATIC HER2 NEGATIVE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (LEAP-015) — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY OF NEOADJUVANT-ADJUVANT DURVALUMAB AND FLOT CHEMOTHERAPY FOLLOWED BY ADJUVANT DURVALUMAB IN PATIENTS WITH RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC) (MATTERHORN) — RECRUITING · PHASE3
• A MULTICENTER, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, DOSIMETRY, AND PRELIMINARY EFFICACY OF THE HER2-DIRECTED RADIOLIGAND CAM-H2 IN PATIENTS WITH ADVANCED/METASTATIC HER2-POSITIVE BREAST, GASTRIC, GASTROESOPHAGEAL JUNCTION, AND OTHER HER2-POSITIVE SOLID TUMORS — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND CLINICAL STUDY OF PEMBROLIZUMAB (MK-3475) PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH HER2 NEGATIVE, PREVIOUSLY UNTREATED, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (KEYNOTE-859) — RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL OF RELATLIMAB (ANTI-LAG-3) PLUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT IN PATIENTS WITH GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA — RECRUITING · PHASE2
• A PHASE 3, GLOBAL, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, EFFICACY STUDY OF IMAB362 PLUS MFOLFOX6 COMPARED WITH PLACEBO PLUS MFOLFOX6 AS FIRST-LINE TREATMENT OF SUBJECTS WITH CLAUDIN (CLDN)18.2-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) PLUS CHEMOTHERAPY (XP OR FP) VERSUS PLACEBO PLUS CHEMOTHERAPY (XP OR FP) AS NEOADJUVANT/ADJUVANT TREATMENT FOR SUBJECTS WITH GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA (KEYNOTE-585) — RECRUITING · PHASE3
• A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER — RECRUITING · PHASE3
• A PHASE IB/2 STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB, MEDI4736 MONOTHERAPY, AND TREMELIMUMAB MONOTHERAPY IN SUBJECTS WITH METASTATIC OR RECURRENT GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA — RECRUITING · PHASE1
• A PHASE III OPEN-LABEL, MULTICENTER TRIAL OF MAINTENANCE THERAPY WITH AVELUMAB (MSB0010718C) VERSUS CONTINUATION OF FIRST-LINE CHEMOTHERAPY IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, ADENOCARCINOMA OF THE STOMACH, OR OF THE GASTRO-ESOPHAGEAL JUNCTION — RECRUITING · PHASE3
• "A PHASE III, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERUS PACLITAXEL IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WHO PROGRESSED AFTER FIRST-LINE THERAPY WITH PLATINUM AND FLUOROPYRIMIDINE." — RECRUITING · PHASE3
• A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB AS MONOTHERAPY AND IN COMBINATION WITH CISPLATIN+5-FLUOROURACIL IN SUBJECTS WITH RECURRENT OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (KEYNOTE-059) — RECRUITING · PHASE2
• Study for AZD4360 in Participants With Advanced Solid Tumours — ACTIVE_NOT_RECRUITING · PHASE1
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. — TERMINATED · PHASE1
• AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 — ACTIVE_NOT_RECRUITING · PHASE2
• Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging — NOT_YET_RECRUITING
• Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction — ACTIVE_NOT_RECRUITING · PHASE2
• Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) — COMPLETED · PHASE3
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension — COMPLETED · PHASE3
• PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma — NOT_YET_RECRUITING · PHASE3

Refine this search